Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DDZ48Y
|
|||
| Drug Name |
Sugemalimab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25] | Approved in China | [1] | |
| Extranodal NK/T-cell Lymphoma [ICD-11: 2A90.6] | Phase 3 | [2] | ||
| Company |
EQRx
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death 1 ligand 1 (PD-L1) | Target Info | . | [3] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Reactome | PD-1 signaling | |||
| WikiPathways | Costimulation by the CD28 family | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599. | |||
| REF 2 | ClinicalTrials.gov (NCT05700448) A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL). U.S.National Institutes of Health. | |||
| REF 3 | Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.